Boston Scientific is strengthening its electrophysiology and structural heart segments as it has acquired Baylis Medical Company. The Marlborough, MA-based company first announced the $1.75 billion deal in October of 2021.

Austin, TX-based Baylis Medical is known for its advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures.

“The close of this acquisition allows Boston Scientific to integrate the Baylis platforms with our existing electrophysiology and structural heart offerings, further strengthening our position within the highest growth cardiology markets,” said Joe Fitzgerald, executive vice president and president, Cardiology, Boston Scientific. “We are now the only company to pair a comprehensive access portfolio with existing left-heart therapies such as left atrial appendage (LAA) closure and atrial fibrillation ablation, providing physicians with a complete toolbox to treat patients with safety, efficacy and efficiency.”

The addition of Baylis could significantly boost Boston Scientific’s already well-performing Watchman LAA device.

In a research note, BTIG analyst Marie Thibault wrote, “WATCHMAN reportedly exceeded Q4 expectations; full-year sales were $830M (+68% vs. 2019). We continue to view competition as a ‘rising tide’ for LAAC market growth.”

Baylis is just one of several deals Boston Scientific announced in 2021. The company went on a buying spree revealing its intent to acquire a total of five different companies. However, Boston Sci’s 2021 buying spree pales in comparison to its M&A appetite in 2018.

But it doesn’t look like 2022 will be a year short on deals.

Boston Scientific CFO Dan Brennan said, “Our top priority for capital remains high-quality tuck-in M&A, and we’ll continue to assess opportunities in conjunction with our financial goals,” according to a Seeking Alpha transcript of the company’s most recent earnings call.

Article source: Qmed and MD+DI